Soleno Therapeutics Common Stock Net 2013-2025 | SLNO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Soleno Therapeutics common stock net from 2013 to 2025. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Soleno Therapeutics common stock net from 2013 to 2025. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$75.5B
Zoetis (ZTS)	$67.5B
Takeda Pharmaceutical (TAK)	$46.8B
Daiichi Sankyo, - (DSNKY)	$44.2B
BeOne Medicines - (ONC)	$30.6B
Sandoz Group AG (SDZNY)	$24.9B
Summit Therapeutics (SMMT)	$21B
Merck (MKKGY)	$16.7B
Shionogi (SGIOY)	$14.2B
United Therapeutics (UTHR)	$13.4B
Neurocrine Biosciences (NBIX)	$13.2B
Orion OYJ (ORINY)	$11B
IPSEN (IPSEY)	$10.2B
Stevanato Group S.p.A (STVN)	$7.7B
Corcept Therapeutics (CORT)	$7.7B
Madrigal Pharmaceuticals (MDGL)	$7.7B
Grifols, S.A (GRFS)	$6.9B
Ionis Pharmaceuticals (IONS)	$6.8B
Hikma Pharmaceuticals Plc (HKMPF)	$6.2B
Ono Pharmaceutical (OPHLF)	$5.2B
Hypermarcas (HYPMY)	$3.2B
Crinetics Pharmaceuticals (CRNX)	$3B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.6B
NewAmsterdam Pharma (NAMS)	$2.3B
Centessa Pharmaceuticals (CNTA)	$2.1B
BioCryst Pharmaceuticals (BCRX)	$1.8B
Ocular Therapeutix (OCUL)	$1.8B
ARS Pharmaceuticals (SPRY)	$1.8B
Endo (NDOI)	$1.6B